Marcin Bielówka

Founder and CEO

10 past transactions

Digital First AI

Pre Seed Round in 2022
Digital First AI offers a platform that enables users to create and execute marketing strategies quickly using AI-generated content and tactics. The service includes a library of proven marketing tactics, funnel management tools, and collaboration features for teams. It aims to simplify the marketing process for businesses of all sizes, helping them optimize their campaigns efficiently.

prints.me

Pre Seed Round in 2020
We are a B2B Marketplace offering full support in printing services for companies around Europe. We deliver high quality print products containing all available print technologies on the market plus creative and product design, print process management with quality staging and logistic for the best Customer Success. We are all-in-one solution for any company, delivering time and cost savings, keeping the high quality production. It's simple, professional, it's easy... just prints me!

SKY ENGINE AI

Pre Seed Round in 2020
SKY ENGINE AI is a synthetic data cloud generative AI platform for data scientists enabling ai computer vision at scale software allows creating a digital twin of your sensor, drone, or robot and putting them through testing and training in a virtual environment prior to real-world deployment. They are data generation makes data scientist life easier providing perfectly balanced datasets for any computer vision applications like object detection and recognition. They include 3d positioning, pose estimation, and other sophisticated cases including analysis of multi-sensor data radars, lidars, satellites, x-rays, and more.

ARAHUB

Pre Seed Round in 2019
ARAHUB - integrated system for behavioral targeting advertisement in digital outdoor, which enable the analysis of recipient: gender, age, interests and shopping intentions, and is able to assess their response to a message.

WIDMO Spectral Technologies (formerly SGPR.TECH)

Seed Round in 2019
We build a unique solution for subsurface tomography based on spectral ground penetrating radar and advanced analytical software, to deliver geological information of unprecedented quality. With our solution, we aim to change how subsurface-information-dependent industries, such as construction or raw materials, are gathering and analysing subsurface data—providing the solution which will produce ready-to-use models and information—addressing industries' problems at every stage of their projects.

SiDLY

Seed Round in 2017
SiDLY is a rapidly growing company specializing in telemedicine through its innovative AI medical technology. The firm offers a comprehensive platform that combines eHealth and eCare, enabling individuals to access medical diagnostics and conduct ongoing health monitoring remotely. Its flagship product, the SiDLY medical wristband, works in conjunction with an AI-based telemedicine system and a mobile application, facilitating effective medical services while reducing reliance on institutional care. With a repository of over 380 million qualitative medical data points, SiDLY is positioned to create valuable AI-driven health services. In recognition of its growth and impact in the sector, the company was named the fastest-scaling technology firm in 2023 by Deloitte's CE Technology Fast 50.

PolTREG

Seed Round in 2015
PolTREG is a biotechnology company focused on developing innovative therapies using T-regulatory cells (TREGs) for the treatment of autoimmune diseases, notably type 1 diabetes and multiple sclerosis. Established as a spin-off from the Medical University of Gdańsk, the company aims to commercialize its patented TREG method, which has shown promising results in clinical trials. PolTREG's portfolio includes four advanced projects currently in clinical development, backed by a team of experienced managers, biotechnology specialists, and scientists. The founders bring over 17 years of expertise in T-regulatory cell applications for autoimmune therapies. The company's Scientific Advisory Board comprises leading experts in the field, ensuring a strong foundation for research and development. PolTREG is uniquely positioned as the sole entity authorized to implement its research findings and utilize its growth method for clinical applications, with a commitment to delivering its breakthrough therapies to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.